company background image
IMV

IMV TSX:IMV Stock Report

Last Price

CA$0.87

Market Cap

CA$71.7m

7D

33.8%

1Y

-54.5%

Updated

15 Aug, 2022

Data

Company Financials +
IMV fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

IMV Stock Overview

IMV Inc. operates as a clinical-stage immuno-oncology company.

IMV Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for IMV
Historical stock prices
Current Share PriceCA$0.87
52 Week HighCA$2.40
52 Week LowCA$0.60
Beta1.85
1 Month Change17.57%
3 Month Change-33.08%
1 Year Change-54.45%
3 Year Change-77.98%
5 Year Change-77.72%
Change since IPO-76.36%

Recent News & Updates

Shareholder Returns

IMVCA BiotechsCA Market
7D33.8%-3.5%2.5%
1Y-54.5%13.7%1.0%

Return vs Industry: IMV underperformed the Canadian Biotechs industry which returned 11.1% over the past year.

Return vs Market: IMV underperformed the Canadian Market which returned 0.7% over the past year.

Price Volatility

Is IMV's price volatile compared to industry and market?
IMV volatility
IMV Average Weekly Movement13.1%
Biotechs Industry Average Movement13.0%
Market Average Movement10.6%
10% most volatile stocks in CA Market18.9%
10% least volatile stocks in CA Market4.3%

Stable Share Price: IMV is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: IMV's weekly volatility (13%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
200097Andrew Hallhttps://www.imv-inc.com

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company’s lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer.

IMV Inc. Fundamentals Summary

How do IMV's earnings and revenue compare to its market cap?
IMV fundamental statistics
Market CapUS$55.61m
Earnings (TTM)-US$42.68m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMV income statement (TTM)
RevenueUS$0
Cost of RevenueUS$25.80m
Gross Profit-US$25.80m
Other ExpensesUS$16.89m
Earnings-US$42.68m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.52
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio1,168.2%

How did IMV perform over the long term?

See historical performance and comparison